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ASSESSING INTERFERON-ALPHA MONOTHERAPY IN PATIENTS WITH 
ADVANCE OR METASTATIC RENAL CELL CARCINOMA
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OBJECTIVES: The objective was to evaluate the clinical efﬁ cacy and safety of inter-
feron-α 2a (IFN) in the treatment of advanced/metastatic renal cell carcinoma in 
treatment-naïve patients. METHODS: Studies were retrieved from Embase, Pubmed, 
Cochrane, and DARE databases using relevant search strategies. Randomized con-
trolled trials, which compared IFN with other pharmacological interventions/best 
supportive care (BSC), were included according to prespeciﬁ ed inclusion/exclusion 
criteria. The outcomes of interest were overall survival (OS), progression free survival 
(PFS), response rate (RR), and adverse events (AEs). Two reviewers independently 
extracted data from the included studies. Data were analyzed using RevMan (5). 
RESULTS: Of the 736 studies identiﬁ ed, seven studies met the inclusion criteria. In 
total, 1147 patients were randomized to IFN, and 1150 were randomized to compara-
tor interventions. Two studies reported comparison with interleukin-2 (IL-2), two with 
BSC and one each with sorafenib, sunitinib, and temsirolimus. Median OS ranged 
from 9 to 21.8 months with IFN. Progression-free survival ranged from 1.9 to 5.6 
months and overall RR ranged from 4.83% to 12.27% with IFN. Sunitinib had sig-
niﬁ cantly better overall RR (P < 0.001), PFS (P < 0.001), and OS (P < 0.01) compared 
to IFN. Sorafenib and temsirolimus had better overall RR than IFN (P < 0.01). Results 
of meta- analysis demonstrate that IFN has better overall RR than BSC (OR: 2.51 
[95% CI: 0.87, 7.27], P = 0.089) and similar RR as IL-2 (OR: 1.09 [95% CI: 0.48, 
2.45], P = 0.836). The AE proﬁ le (gastrointestinal, vascular, infectious, and blood 
disorders) was similar with IFN and comparators. CONCLUSIONS: Survival beneﬁ t 
with IFN-α was lower than the newer therapeutic agents. Anti-angiogenic agents 
targeting through multiple receptor kinases, such as sunitinib and sorafenib have 
signiﬁ cantly improved response rates and survival. These agents would be preferred 
for treatment naïve patients with advanced/metastatic renal cancer.
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OBJECTIVES: As overall survival improves with newer therapies for mCRC, treatment-
limiting toxicities and related costs will be important when evaluating treatment deci-
sions. Little is known about toxicity-related cost of currently available monoclonal 
antibody treatments. This study was designed to identify cetuximab-, bevacizumab-, and 
panitumumab-related toxicities and estimate direct costs of treating these toxicities. 
METHODS: A comprehensive literature search was performed to identify English 
language phase II/III studies of monoclonal antibodies for mCRC. The search utilized 
PubMed, conference abstracts, treatment guidelines, and product labels. Commonly 
reported grade 3 and 4 toxicities were identiﬁ ed, and outpatient and inpatient costs 
were estimated for all toxicities. Outpatient costs were estimated by applying 2010 
Medicare reimbursement rates to resource use assumptions (assessed based on in-
depth clinical interviews). Inpatient costs were estimated using ICD-9 codes and 2007 
Medicare payments from the HCUP database; then were converted to 2010 values 
using the Consumer Price Index for medical care services. RESULTS: Clinically sig-
niﬁ cant toxicities associated with bevacizumab include hypertension, arterial throm-
bosis, hemorrhage, gastrointestinal (GI) perforation, ﬁ stula, and wound healing 
complication; while treatment-related toxicities associated with cetuximab and pani-
tumumab include skin rash, hypomagnesemia, and infusion reactions, although the 
incidence of these toxicities differ between the two drugs. Cost of toxicities treated in 
outpatient setting ranged from $185 (hypertension and skin rash) to $585 (wound-
healing complications). Inpatient cost per event for GI perforation is the highest at 
$32,443, followed by ﬁ stula $29,062, arterial thrombosis $20,346, wound healing 
complication $13,240, hemorrhage $12,956, infusion reaction $10,326, and hyperten-
sion $8453, while inpatient cost per event for skin rash and hypomagnesemia is among 
the lowest at $4424 and $6174, respectively. CONCLUSIONS: Monoclonal antibod-
ies have different toxicity proﬁ les and the costs associated with managing these toxici-
ties vary greatly.
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OBJECTIVES: Few data are available about the use of erlotinib in real-life in France 
for patients with non small cell lung cancer (NSCLC) in a selected population. 
METHODS: An epidemiological multicenter observational study was built in 35 
french centers. The study was retrospective (2006 to 2008) and a cohort was created 
with a follow-up period of 1 year. The main objective was to describe practices, use 
of erlotinib, response, and adverse events. RESULTS: A total of 533 patients (333 
males, 200 females) have been included. The histological types were as follows: 330 
(62.5%) adenocarcinoma, 107 (20.2%) squamous cell carcinoma, 60 (11.3%) large 
cell carcinoma, 36 (3.8%) undifferentiated carcinoma. In terms of practice, 502 
patients had a ﬁ rst line chemotherapy (81% a doublet, 11% three drugs, 8.2% one 
drug). Among them, 61.2% received a second line of treatment (83.4% one drug, 
15.7% two drugs and 0.9% three drugs), 17.6% received a third line (91% one drug). 
Erlotinib was prescribed a ﬁ rst line treatment (n = 30; 5.6%), second line treatment 
(n = 190; 35.6%), third line (255; 47.8%), fourth line, and more (n = 50; 9.3%) and 
as a maintenance therapy (n = 9; 1.7%); the stage at treatment initiation were stage 
I–II (1.2%), IIIA (3.8%), IIIB (5.3%), and IV (89.7%). For the ﬁ rst line, the median 
duration of erlotinib treatment was 123 days (d) in second line 98 d, in third line 
77 d, in maintenance 127 d. Global response rate was 20% with a maximum of 32% 
in ﬁ rst line and 33% in maintenance. Grade III adverse events occurred in 11.5% of 
patients and grade IV in 3.4%. CONCLUSIONS: Erlotinib was widely used in France 
in 2d and 3d line treatment with a good response rate and tolerance. Adenocarcinoma 
is the main indication.
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EXPLORATIVE ANALYSIS ABOUT THE POTENTIAL OF A LARGE GPS 
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AMONG PATHOLOGIES
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OBJECTIVES: The main objective of this study was to analyze different approaches 
and methods to explore potential causal associations among prevalent pathologies. 
We have focused on diabetes mellitus (DM) and its well-known association with 
incident neoplasia. METHODS: For this retrospective cohort study, data were 
obtained from CSD LPD, a General Practitioner’s longitudinal database. We have 
evaluated the risk of neoplasia incidence among people with diabetes mellitus com-
pared with those without this pathology, in patients who had no reported history of 
benign or malign neoplasia at the start of the follow-up on January 2006. For the DM 
group, patients with at least one diagnosis of DM from January 2005 to December 
2005 have been selected, while for the DM-free group, patients without a diagnosis 
of DM and a date of registration in the GPs ofﬁ ce before January 2006 have been 
selected. Both groups have been followed up for 48 months. RESULTS: During the 
selection period, 45.121 (3.4%) patients with a diagnosis of DM (females: 22.330, 
males: 22.791) and 1.290.597 (96, 6%) patients without a diagnosis of DM (females: 
690.462, males: 600.135) have been selected. During the follow-up 6.648 and 80.880 
incident cases of neoplasms have been documented from the DM and DM free groups 
respectively. The mean follow-up duration was 43 and 45 months for the DM and 
the DM-free groups respectively. CONCLUSIONS: The selected cohort has shown to 
match quite well with general population in terms of gender and age. The estimated 
prevalence of diabetes also matches with the one of the general population. Statistical 
analysis has shown an adjusted (for age and sex) hazard ratio of 1,88 (95% Cl 
1,83–1,93) suggesting an association between DM and incident neoplasms, evidencing 
that GPs longitudinal databases could be a valid instrument for evaluating causal 
association among prevalent pathologies.
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OBJECTIVES: Objective response rate (ORR) is an early indicator of successful treat-
ment in patients with NSCLC. This research compared geﬁ tinib with platinum-based 
doublet chemotherapies for ﬁ rst-line treatment of advanced NSCLC in patients harbor-
ing activating epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations 
(M+). METHODS: Systematic searching of CENTRAL, EMBASE, and MEDLINE for 
randomized controlled trials (RCTs) comparing ≥2 doublet chemotherapies (carbopla-
tin or cisplatin in combination with either docetaxel, gemcitabine, paclitaxel, peme-
trexed, or vinorelbine) for the ﬁ rst-line treatment of advanced NSCLC was completed 
in May 2009. a meta-analysis was performed on ORR using data from published 
RCTs of geﬁ tinib versus paclitaxel/carboplatin in EGFR-TK M+ patients. a mixed 
treatment comparison (MTC) was carried out with doublet chemotherapies in 
unselected advanced NSCLC patients using paclitaxel/carboplatin as a baseline. Treat-
ment effect was calculated as an odds ratio (OR) with 95% credible interval (95% 
CrI). a sensitivity analysis was conducted on the inclusion of the geﬁ tinib trials within 
the MTC. For this analysis, it was assumed that the efﬁ cacy of doublet chemotherapy 
is consistently affected by EGFR-TK mutation status. RESULTS: Three RCTs were 
identiﬁ ed for geﬁ tinib, of which two were comparisons with paclitaxel/carboplatin. 
Meta-analysis of these two trials gave an estimated ORR favoring geﬁ tinib: OR 4.04, 
95% conﬁ dence interval: 2.73–5.98. Twenty-nine trials were appropriate for inclusion 
in the MTC, of which 25 reported ORR. The MTC found no signiﬁ cant difference in 
ORR among other doublet chemotherapies versus paclitaxel/carboplatin, with the 
exception of pemetrexed/cisplatin, in patients with predominantly non-squamous 
tumor cell histology, which was associated with a signiﬁ cantly higher ORR (OR 1.64, 
95% CrI: 1.15–2.27). In the sensitivity analysis, ORR was signiﬁ cantly higher with 
